SpaceX Lockup Test Meets Biotech IPO Pipeline as SEC Rewrites Market Plumbing

Today’s SpaceX Lockup: A Float Multiplier

At market open on August 6, approximately 912 million SpaceX (SPCX) shares become eligible for sale — more than doubling the company’s current public float.^[1] SpaceX went public on June 12 at $135 per share, and the stock has since tumbled 49% from its June high and roughly 15% below the IPO price.^[2]

The lockup expiry arrives two days after SpaceX’s first-ever earnings report. On August 4, the company posted $7.81 billion in Q2 revenue, a 92% year-over-year jump that beat analyst estimates of $6.93 billion, though shares fell about 7–8% in extended trading as capital expenditures topped expectations.^[1]

The lockup mechanics are unusual: rather than releasing all restricted shares on a single day, the underwriting syndicate staggered the releases over nearly a year. Today’s tranche alone could more than double the tradable float, and if a price-based early-release provision is triggered, it could more than triple it. By mid-2027, an additional 12.9 billion shares will have been freed up.^[2]

Brokers expect heavy selling. Robert Hackel, CEO of institutional brokerage R.F. Lafferty & Co., called it “the most talked-about lockup in the history of IPO lockups” and said he has been fielding calls from pre-IPO investors looking to sell SpaceX shares to fund positions in other private companies eyeing IPOs, including Anthropic, OpenAI, and Anduril Industries.^[2]

CEO Elon Musk’s roughly 42% stake remains locked for a full year under a separate agreement. Executive officers are also subject to longer lockups that generally do not begin expiring until after Q4 results. The question is whether employees and early financial backers — including Founders Fund, Craft Ventures, Valor Equity Fund, and Alphabet — take profits or hold.^[2]

The base-rate read: staggered lockups typically produce a volatility spike around the first expiry, then settle as the market digests the new supply. Renaissance Capital’s senior strategist Matt Kennedy noted that SpaceX employees and early investors are “sitting on such massive gains that they’ll have a very strong incentive to realize a return and diversify their holdings.”^[2] But Falcon Wealth Planning’s Gabriel Shahin, who has been polling SpaceX insider contacts, reports that none appear eager to sell, calling them “long-term believers.”^[2]

The honest assessment: today’s trading volume and price action will tell us more about real selling pressure than any forecast. The VIX closed at 15.81 on August 5, down from 20.66 on July 29, suggesting the broad market is in a low-volatility regime that could absorb supply — but a single-name float shock operates on its own dynamics.^[3] I’d put the odds of an orderly absorption at roughly 60/40, with the 40% scenario involving concentrated early selling that triggers the price-based early-release provision and compounds the pressure.

August IPO Calendar: Biotech Dominates, Consumer Tests the Waters

Six IPOs are on the calendar for the week of August 3, five of them biotechs.^[4]

Braveheart Bio, a cardiovascular disease biotech developing an oral cardiac myosin inhibitor licensed from Hengrui Pharmaceuticals, priced its upsized IPO at $18 per share on August 6, above the $15–$17 range — an early signal that biotech demand remains strong.^[5]

The broader IPO market context is mixed. Renaissance Capital’s July update reported eight IPOs raising a combined $29.3 billion in July — but that figure was dominated almost entirely by Korea-listed SK hynix, which raised $26.5 billion in the largest-ever US equity offering from a foreign issuer. Excluding SK hynix, deal flow came in well below the historical monthly mean of 20 IPOs.^[6]

Persistent volatility from AI spending fears and geopolitical tensions held back deal flow, and the Renaissance IPO Index sank 14% in July, underperforming the S&P 500’s flat return.^[6] Year-to-date, 86 IPOs have priced, down 23.2% from the same date in 2025.^[5] The Renaissance IPO Index was up 14.8% YTD through July 30, versus the S&P 500’s 9.4%.^[4]

One notable signal: the IPO window is starting to broaden beyond AI infrastructure and biotech. Jersey Mike’s (JMKE) raised $1 billion in July but was met with muted demand — a reminder that the market’s appetite for consumer names remains selective.^[6]

Can the Market Absorb the Supply?

The supply-demand math is the critical question, and the evidence points in both directions.

On the demand side, buybacks are expected to reach $1.5 trillion in 2026, according to J.P. Morgan Private Bank strategists — more than the total equity issuance expected this year and potentially sufficient to fully offset new supply. M&A announcements hit a record $900 billion in the first half of 2026.^[7] Households have shifted from net sellers in prior cycles to net buyers, with net household demand at 3% of total corporate equity value.

On the supply side, over $260 billion of equity issuance is expected this year, near 2021 levels. But the S&P 500’s market cap has grown to roughly $65 trillion — about 55% larger than in 2021 — meaning IPO supply is approximately 1% of total market cap. J.P. Morgan’s analysis suggests that even a hypothetical $2 trillion IPO with a 10% float would require selling by benchmark indices equivalent to only one to two days of average daily trading volume in the S&P 500’s largest weights.

The base rate here is reasonably constructive. Two-thirds of the 25 largest IPOs in history were followed by positive S&P 500 returns in the subsequent 12 months, with gains between 5% and 20%. But that base rate was established in a lower-rate, lower-geopolitical-risk regime. The 40% scenario — where supply overwhelms demand — would require a simultaneous downturn in buyback activity, a freeze in M&A, and a shift in household sentiment. None of those are evident today, but the staggered SpaceX lockup releases running through mid-2027 add a persistent overhang that doesn’t show up in annual supply totals.^[2]

SEC Proposes Rescinding Reg NMS Rule 611

While the market digests new supply, the SEC is proposing the most significant structural change to US equity trading in two decades. On June 11, the Commission voted to propose rescinding Rule 611 (the trade-through prohibition, also known as the Order Protection Rule) and Rule 610(e) (the locked and crossed markets prohibition) of Regulation NMS.^[8]

Rule 611, adopted in 2005, requires every trading center to establish policies and procedures to prevent “trade-throughs” — executions at prices inferior to protected quotations displayed on other exchanges.^[9] It was intended to ensure that investors who post limit orders receive price priority across the national market system.^[9]

Chairman Paul Atkins, who dissented from the original adoption of Rule 611 as a commissioner in 2005, described the rule as having “hindered — rather than enhanced — the long-term growth of our markets” and said the proposal aims to “simplify market structure and reduce costs for market participants.”^[8]

The SEC’s case for rescission rests on several observations:

• Exchange proliferation: In 2005, approximately eight exchanges traded NMS stocks. Today, there are 17 operating exchanges with three more approved. Rule 611 effectively guarantees that any new exchange displaying a protected quote receives order flow, driving up connectivity costs and fragmenting liquidity.^[9]
• Cost burden: The SEC estimates that a broker-dealer connecting to all exchanges spends approximately $5.7 million per year on market data and connectivity fees, with onboarding a new exchange costing an estimated $1.5 million plus $200,000 in annual maintenance.^[9]
• Harm to institutional investors: For institutions executing large orders, the rule can force interaction with small-sized protected quotes across many venues, potentially signaling trading intentions and increasing slippage.^[9]
• Best execution as a safeguard: The SEC argues that broker-dealers’ existing duty of best execution under FINRA Rule 5310 will continue to protect investors.^[9]

Not everyone is convinced. At SEC roundtables, some participants argued that best execution as currently constituted is “neither enforced nor enforceable” and that weakening Rule 611 “must be accompanied by improvements to best execution,” including 605/606 reforms and adding odd lots to the SIP.^[9] Former Commissioner Caroline Crenshaw cautioned against assuming that “doing away with the order protection rule is a magic bullet.”^[9]

The public comment period remains open for 60 days following Federal Register publication.^[8]

The trajectory here matters. Commissioner Mark Uyeda described the proposal as “the beginning of a broader, more complex journey of reforming the Commission’s equity market-structure rules,” comparing the existing regulatory regime to “the threads of a sweater — pull one thread, you inevitably stress others.”^[9] The SEC also flagged that distributed ledger technology and tokenization raise challenges for current equity market structure — a signal that this rescission could be the first step toward a more fundamental rearchitecture.^[9]

What to Watch Next

1. SpaceX float absorption (today through August 30): Today’s volume and price action are the first read. Watch for whether the stock stabilizes above its post-earnings lows or breaks to new lows. A price-based early-release provision could trigger additional share unlocks, compounding pressure.^[2]

2. Biotech IPO reception (this week through mid-August): Braveheart Bio priced above range — a positive signal. Watch first-day performance for the remaining five deals. Strong demand supports the fall pipeline; weak demand could delay filings.^[4]

3. Reg NMS comment letters (through roughly August): The 60-day comment window will reveal whether institutional investors and broker-dealers support full rescission or push for alternatives like volume-based thresholds for protected quote status. Watch for FINRA’s position on best execution guidance.^[9]

4. Staggered SpaceX lockup schedule (through mid-2027): Today’s 912 million shares are the first tranche. Each subsequent release adds tradable supply and tests investor conviction. The schedule runs for roughly 12 months.^[2]

5. IPO pipeline breadth (September through October): Renaissance Capital expects several deals to slip in before the annual summer pause. The key question is whether the window broadens beyond biotech and AI infrastructure, or narrows if volatility returns.^[6]